Show simple item record

dc.contributor.authorMacaskill, Elizabeth Janeen
dc.date.accessioned2018-03-29T12:18:24Z
dc.date.available2018-03-29T12:18:24Z
dc.date.issued2010
dc.identifier.urihttp://hdl.handle.net/1842/29235
dc.description.abstracten
dc.description.abstractThe mammalian target of rapamycin (mTOR) plays a key role in tumour cell cycle control, proliferation and survival, and has been implicated in resistance to endocrine therapy in breast cancer. RAD001 (everolimus) is a novel macrolide that inhibits mTOR and its downstream substrates in vitro. This study explores the use of RAD001 at a dose of 5mg daily in women with early breast cancer. 31 postmenopausal women were given RAD001 for 14 days prior to primary surgical intervention for early breast cancer. RAD001 was well tolerated in most patients, 5 did not complete treatment due to drug adverse effects. Tumour samples before (pre) and after (post) 14 days treatment were assessed for changes in proliferation and markers of the mTOR pathway. Significant reductions in proliferation (Ki67) and oestrogen receptor (ER) expression were seen, and the downstream effects of the mTOR pathway inhibited (p-S6 (ser235/236 and ser 240/244) and nuclear expression of p-Akt). Gene expression profiling from these tumour samples has confirmed these findings, demonstrating reduction in expression of proliferative genes and oestrogen dependence genes with RAD001 treatment. The mTOR protein exists in two distinct complexes, raptor and rictor, and it has previously been thought that mTOR inhibitors such as RAD001 only have effects upon raptor. The implication of this if correct would be upregulation of Akt (Protein Kinase B), which has been shown to be present in more aggressive and resistant tumour types. The cell line study described herein has demonstrated no upregulation in p-Akt expression with RAD001 treatment, and in one cell line inhibition of p-Akt was sustained with prolonged cell treatment.en
dc.publisherThe University of Edinburghen
dc.relation.ispartofAnnexe Thesis Digitisation Project 2018 Block 17en
dc.relation.isreferencedbyAlready catalogueden
dc.titleThe mammalian target of rapamycin inhibitor RAD001 (everolimus) in early breast canceren
dc.typeThesis or Dissertationen
dc.type.qualificationlevelDoctoralen
dc.type.qualificationnameMD Doctor of Medicineen


Files in this item

This item appears in the following Collection(s)

Show simple item record